At a Glance / Aperçu

Licensing agreement signed

Canadian Medical Association Journal 1996; 155: 967

The University of Alberta and SYNSORB Biotech Inc., a Calgary-based biotechnology firm, have signed a licensing agreement for technology that can be used in the treatment of enteropathogenic Escherichia coli infections, one of the most common causes of diarrhea in infants. It was developed by Dr. Glen Armstrong and a research team at the U of A.

| CMAJ October 1, 1996 (vol 155, no 7) |